Price
$28.62-4.47%Social Signal Score
Analyst Ratings
18 analystsRevenue
$41.00MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Terry J. Rosen
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 601
- Beta
- 0.81
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- 0.75
Financials
Revenue
$41.00M+25053.4%Net Income
$-91.00MEBITDA
$-85.00MFree Cash Flow
$-119.00MEPS (diluted)
$-0.72Shares Outstanding (diluted)
126.10M+413.5%Operating Expenses
$137.00MCash & Debt
$702.00MReturn of Capital
$0.00Revenue by Segment (annual)
$253.00MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $247.00M | $-353.00M | $-3.29 |
| 2024 | $258.00M | $-283.00M | $-3.14 |
| 2023 | $117.00M | $-307.00M | $-4.15 |
| 2022 | $112.00M | $-267.00M | $-3.71 |
| 2021 | $383.00M | $53.00M | $0.76 |
| 2020 | $78.00M | $-123.00M | $-2.24 |
| 2019 | $15.00M | $-84.71M | $-1.93 |
| 2018 | $8.35M | $-49.59M | $-1.43 |
| 2017 | $1.41M | $-53.08M | $-2.16 |
| 2016 | $0.00 | $-17.97M | $-0.73 |
Valuation
RCUShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
30-40.00%Social Signal Score
Mentions (6)
- Newsbusinesswire.com·11d ago·Negative
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and inflammatory diseases, today announced that the Compensation Committee of the Company's Board of Directors granted four new employees options to purchase a total of 21,200 shares of the Company's common stock at …
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Arcus Biosciences, Inc. (RCUS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsbusinesswire.com·26d ago·Neutral
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 26,350 shares of the Company's common s…
View source ↗ - Newsseekingalpha.com·26d ago·Positive
Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript Arcus Biosciences, Inc. (RCUS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
Arcus Biosciences Announces New Employment Inducement Grants HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer and inflammatory and autoimmune diseases, today announced that the Compensation Committee of the Company's Board of Directors granted one new employee options to purchase a total of 2,850 shares of the Company's common st
View source ↗ - Newsmarketbeat.com·58d ago·Neutral
Arcus Biosciences Q2 Earnings Call Highlights Arcus Biosciences NYSE: RCUS outlined plans to expand development of its casdatifan cancer program across multiple lines of clear cell renal cell carcinoma, or ccRCC, while reporting second-quarter financial results and updates on its pancreatic cancer and immunology pipelines.
View source ↗
Earnings
Tue, Oct 27(in 3 weeks)
Consensus estimate $-0.88 per share
Typical surprise +12.0% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-0.72 vs $-0.89beat
- Tue, May 5$-1.02 vs $-0.92miss
- Wed, Feb 25$-0.89 vs $-1.11beat
- Tue, Oct 28$-1.27 vs $-1.33beat
- Wed, Aug 6$-0.08 vs $-1.14beat
- Tue, May 6$-1.14 vs $-1.02miss
Estimates and results for RCUS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RCUS officers and directors.
- Bought
- —
- Sold
- $14.4m
0 trades
46 trades
- Azoy Alexandersold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
- Jaen Juan C.sold
54 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RCUS.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.